Hims vs MEDVidi
Hims and MEDVidi sell different medications; this is what separates them.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Hims
Best for: knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC
Visit Hims →If you are choosing between Hims and MEDVidi, price alone will not settle it. Hims leads our six-part score, 6.8 to 4.4. One of the two has an FDA warning letter on record, covered below.
Hims vs MEDVidi price
Hims publishes $199 a month. MEDVidi does not post a GLP-1 price we can quote, so you would only learn its cost after an intake.
Medications and formats
Hims lists semaglutide and tirzepatide; MEDVidi does not name its drug.
On format, Hims prices compounded injections and brand-name pens, while MEDVidi posts no priced format.
If you want the FDA-approved brand rather than a compounded version, Hims is the only one of the two with a brand-name price.
Where each one treats patients
Hims lists 50 states, and MEDVidi does not publish where it ships.
Pricing
Hims
Brand Zepbound from $299/mo medication-only; requires Hims Weight Loss Membership ($149/mo)
MEDVidi
Pricing not publicly listed.
What each price covers
Hims' price also covers the medication itself, which MEDVidi does not claim.
MEDVidi's price also covers the clinician visit, which Hims does not claim.
Hims is silent on shipping and lab work.
MEDVidi is silent on lab work and coaching.
That matters most for the drug: unless MEDVidi confirms otherwise, budget for medication on top of its listed price.
Hims
Covered by the monthly price
Medication
In the price
Clinician visits
Charged on top
Shipping
Not stated
Lab work
Not stated
Coaching
Charged on top
MEDVidi
Covered by the monthly price
Medication
Charged on top
Clinician visits
In the price
Shipping
Charged on top
Lab work
Not stated
Coaching
Not stated
Where each one scores higher
Overall, Hims scores 6.8 and MEDVidi 4.4 out of 10.
Hims is stronger on effectiveness (10.0 vs 5.0), user experience (8.0 vs 5.0), trust & safety (7.0 vs 4.0) and accessibility (10.0 vs 5.0).
MEDVidi is stronger on support (5.0 vs 3.0).
Value is within half a point.
Hims
6.8/10
MEDVidi
4.4/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
The FDA sent Hims a warning letter dated September 9, 2025 (letter 716567), and it is still open.
MEDVidi has no FDA warning letter on record with us.
Features & Coverage
| Feature | Hims | MEDVidi |
|---|---|---|
| Starting Price | $199/mo | Not published |
| Features | 2 features | ✓6 features |
| States Available | 50 | Not disclosed |
| Compounded | ✓ Yes | — |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warning Letters | 1 letter | ✓None |
About Hims
Hims is a major men's telehealth brand. Its weight loss offering is compounded semaglutide on a 6-month plan.
Read our full Hims review →About MEDVidi
Each visit carries its own charge instead of a bundled subscription: 195 dollars to start, 159 dollars for a follow-up. Because the prescription travels to whichever pharmacy the patient picks, the drug is billed apart. Providers holding licenses evaluate patients and write phentermine, Qsymia and Saxenda alongside the brand-name Wegovy (semaglutide) and Zepbound (tirzepatide). The footprint is 33 states. Do not confuse the brand with MEDVi, which is a different company.
Read our full MEDVidi review →Pros & Cons
Hims
What we like
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication
- Serves all 50 states
- Names 4 pharmacies that fill its prescriptions, which most sellers do not
Watch-outs
- Not included in the monthly price: clinician visits, coaching
- The FDA has issued Hims a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
MEDVidi
What we like
- The monthly price includes clinician visits
- We found no FDA warning letters issued to MEDVidi
Watch-outs
- Not included in the monthly price: medication, shipping
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
Our Verdict
Hims wins this one, 6.8 to 4.4, above all for knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC.
Choose Hims if…
You want knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC and an opening price near $199 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
bmiMD
Starting below a standard dose, with microdose tiers
From $99/mo
Get started →RxSpan MD
Knowing which pharmacy fills the vial: it names Belmar Pharmacy
From $249/mo
Get started →Luvo Health
Moving between compounded and brand without changing seller
From $249/mo
Get started →Hims vs MEDVidi: FAQ
Close alternatives to Hims and MEDVidi
- Hims vs Hers
- Hims vs Care Bare Rx
- Hims vs Concierge MD LA
- Hims vs Corsica Health
- MEDVidi vs Embody
- MEDVidi vs TrimRx
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.